Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E H Gerlach

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Clinical Microbiology|February 1, 1986
In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility testsA L Barry, R N Jones, C Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|November 11, 1991
Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test mediumG V Doern, E H Gerlach, J H Jorgensen, et al.
American Journal of Clinical Pathology|December 1, 1978
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporinsA L Barry, C Thornsberry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1977
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolatesR N Jones, P C Fuchs, T L Gavan, et al.
The American Journal of the Medical Sciences|November 1, 1977
Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolatesP C Fuchs, T L Gavan, E H Gerlach, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strainsR N Jones, M A Pfaller, P C Fuchs, et al.
Journal of Clinical Microbiology|January 1, 1987
Quality control limits for microdilution susceptibility tests with norfloxacinA L Barry, T L Gavan, L W Ayers, et al.
The Journal of Antibiotics|December 1, 1977
Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitinR N Jones, C Thornsberry, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1984
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acidA L Barry, R N Jones, C Thornsberry, et al.
European Journal of Clinical Microbiology|December 1, 1984
3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility testsA L Barry, R N Jones, C Thornsberry, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Clinical Microbiology|February 1, 1986
In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility testsA L Barry, R N Jones, C Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|November 11, 1991
Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test mediumG V Doern, E H Gerlach, J H Jorgensen, et al.
American Journal of Clinical Pathology|December 1, 1978
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporinsA L Barry, C Thornsberry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1977
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolatesR N Jones, P C Fuchs, T L Gavan, et al.
The American Journal of the Medical Sciences|November 1, 1977
Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolatesP C Fuchs, T L Gavan, E H Gerlach, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strainsR N Jones, M A Pfaller, P C Fuchs, et al.
Journal of Clinical Microbiology|January 1, 1987
Quality control limits for microdilution susceptibility tests with norfloxacinA L Barry, T L Gavan, L W Ayers, et al.
The Journal of Antibiotics|December 1, 1977
Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitinR N Jones, C Thornsberry, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1984
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acidA L Barry, R N Jones, C Thornsberry, et al.
European Journal of Clinical Microbiology|December 1, 1984
3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility testsA L Barry, R N Jones, C Thornsberry, et al.
Pageof 9